In recent years, neoadjuvant chemotherapy (NAC) performed before chemoradiotherapy and surgery, has become an important part of the standard treatment for BRCA, especially for patients with human epidermal growth factor receptor-2 (HER2)-positive and triple-negative breast cancer (TNBC) [1]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.